A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

1×10E8 pfu, once, 1 cycle, IT

15 mg/kg/day, 14 days, 1 cycle, PO

25 mg/kg/day, 14 days, 1 cycle, PO

35 mg/kg/day, 14 days, 1 cycle, PO

optimal dose, 14 days, 1 cycle, PO

1,200 mg, once, 1 cycle, IV

3×10E8 pfu, once, 1 cycle, IT

optimal dose, once, 1 cycle, IT